Healthcare for All Lead Image
Healthcare for All Lead Image

Mlolongo Blue Box Clinic, Kenya.

Better Health for All

One thing that has always united us at Johnson & Johnson is our commitment to advancing better health for all. For more than 130 years, this has been the focus of our Company, our business and our people. Health means many things: it’s not only the absence of disease, it’s eradicating the source of disease. It’s not only developing cures, it’s preventing the spread of sickness. It’s not only manufacturing medicines, it’s making them accessible to those who need them. And it’s not only about medicines, it’s about supporting entire healthcare systems and healthcare workers who deliver treatment and care for patients, and ensuring they have the right resources and skills to be effective.

Health means many things, and for Johnson & Johnson, it’s all of them. By harnessing our breadth, scale and legacy of scientific innovation, we strive to change the trajectory of health for humanity. All humanity. Because better health for all means reaching the world’s most vulnerable and underserved populations, addressing diseases that affect specific population segments, supporting low-income communities—especially in times of emergency—and empowering every individual to realize their right to health.

As the largest healthcare company in the world, Johnson & Johnson believes that advancing better health for all is our duty, our inspiration, our privilege and our business.

In this section of the Report, we describe how we have continued to advance better health for all in 2019 by combating and preventing disease, improving access and affordability of healthcare, supporting communities and health workers, and tirelessly driving healthcare innovation.

Key Achievements in 2019

  • To improve access to mental healthcare in Rwanda, we completed the first-ever mental health clinical study and launched the first digital mental health training service in the country, with approximately 50,000 community healthcare workers trained by year's end.
  • We expanded treatment for drug-resistant TB patients by providing SIRTURO (bedaquiline) for over 105,797 patients in 134 countries, and launched five new cross-sector TB R&D collaborations aimed at accelerating the early- to late-stage development of potential new TB medicines and treatment regimens.
  • We continued advancing science to prevent and treat HIV/AIDS by launching the first Phase 3 efficacy study of Janssen's investigational HIV preventative vaccine with global partners. We improved youth HIV therapy and reduced infections in Africa by expanding the New Horizons Collaborative; and we reached over one million adolescent girls and young women through our partnership with DREAMS.
  • We supported the Ebola outbreak response in Rwanda and the Democratic Republic of Congo by donating up to 700,000 regimens of Janssen’s investigational vaccine and providing technology solutions to support the Ebola vaccination campaign.
  • We launched our new Center for Health Worker Innovation to address the global health worker shortage.

Areas of Opportunity

  • Advocate for, and strengthen, multisectoral partnerships to accelerate R&D and delivery, focused on accelerating preventative viral vaccines and transformational treatments to tackle entrenched and emerging pandemic threats, including TB, HIV and Disease X.

  • Work with partners to develop the pathway and supporting evidence to deliver a scalable, quality care model that leverages long-acting injectable medicines in resource-limited settings.
  • Continue to encourage and enable open, candid and evidence-based multi-stakeholder dialogue to engage the global community on empowering health workers, strengthening health systems, overcoming access challenges, and unlocking potential of outcomes-based financing.

Policies and Positions

Our policies and positions relating to Better Health for All are referenced throughout this section. In addition, please visit ESG Policies & Positions on our website.

You are leaving jnj.com and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.
Continue